Non-steroidal anti-inflammatory treatment in cancer cachexia: A systematic literature review

Acta Oncologica

Volumn 52, Issue 1, 2013, Pages 6-17

  Solheim, Tora S ^a,b   Fearon, Kenneth C H ^c   Blum, David ^a   Kaasa, Stein ^a,b  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARNITINE; CELECOXIB; FISH OIL; IBUPROFEN; INDOMETACIN; MEGESTROL ACETATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; THIOCTIC ACID; C REACTIVE PROTEIN;

ABSENCE OF SIDE EFFECTS; ANOREXIA; ASCITES; BODY WEIGHT; CACHEXIA; CANCER PATIENT; CATABOLISM; DRUG EFFICACY; DRUG SAFETY; FALSE POSITIVE RESULT; FOOD INTAKE; GASTROINTESTINAL HEMORRHAGE; HUMAN; MUSCLE MASS; PHYSICAL PERFORMANCE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; VEIN THROMBOSIS; APPETITE; BLEEDING; CANCER FATIGUE; DRUG EFFECT; EPIGASTRIC PAIN; LEAN BODY WEIGHT; META ANALYSIS; MUSCLE STRENGTH; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TREATMENT DURATION; WATER RETENTION; WEIGHT GAIN; WEIGHT REDUCTION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APPETITE; BODY WEIGHT; C-REACTIVE PROTEIN; CACHEXIA; CYTOKINES; EATING; HAND STRENGTH; HUMANS; NEOPLASMS; QUALITY OF LIFE;

EID: 84871421202     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2012.724536     Document Type: Review

References (53)

1. Fearon K C. C ancer cachexia: Developing multimodal therapy for a multidimensional problem . Eur J Cancer 2008; 44 : 1124 - 32 .
2. Fearon K, S trasser F, A nker S D, B osaeus I, B ruera E, Fainsinger RL, et al . Defi nition and classifi cation of cancer cachexia: An international consensus . Lancet Oncol 2011; 12 : 489 - 95 .
3. Yavuzsen T, D avis MP, W alsh D, L eGrand S, L agman R . Systematic review of the treatment of cancer-associated anorexia and weight loss . J Clin Oncol 2005; 23 : 8500 - 11 .
4. Murphy KT, L ynch GS. U pdate on emerging drugs for cancer cachexia . Expert Opin Emerg Drugs 2009; 14 : 619 - 32 .
5. Argiles J M, M oore-Carrasco R, F uster G, B usquets S, Lopez-Soriano FJ . Cancer cachexia: The molecular mechanisms . Int J Biochem Cell Biol 2003; 35 : 405 - 9 . (Pubitemid 36140062)
6. Laviano A, I nui A, M eguid M M, M olfi no A, C onte C, Rossi Fanelli F . NPY and brain monoamines in the pathogenesis of cancer anorexia . Nutrition 2008; 24 : 802 - 5 .
7. Madeddu C, D essi M, P anzone F, S erpe R, A ntoni G, Cau MC, et al . Randomized phase III clinical trial of a combined treatment with carnitine - celecoxib - megestrol acetate for patients with cancer-related anorexia/cachexia syndrome . Clin Nutr Epub 2011 Nov 4 .
8. Lundholm K, K orner U, G unnebo L, S ixt-Ammilon P, Fouladiun M, Daneryd P, et al . Insulin treatment in cancer cachexia: Effects on survival, metabolism, and physical functioning . Clin Cancer Res 2007; 13 : 2699 - 706 . (Pubitemid 46788038)
9. Daneryd P, S vanberg E, K orner U, L indholm E, Sandstrom R, Brevinge H, et al . Protection of metabolic and exercise capacity in unselected weight-losing cancer patients following treatment with recombinant erythropoietin: A randomized prospective study . Cancer Res 1998; 58 : 5374 - 9 . (Pubitemid 28551119)
10. Rogers E S, M acLeod R D, S tewart J, B ird S P, K eogh J W. A randomised feasibility study of EPA and Cox-2 inhibitor (Celebrex) versus EPA, Cox-2 inhibitor (Celebrex), resistance training followed by ingestion of essential amino acids high in leucine in NSCLC cachectic patients - ACCeRT study . BMC Cancer 2011; 11 :493.
11. Induru RR, L agman RL. M anaging cancer pain: Frequently asked questions . Cleveland Clin J Med 2011; 78 : 449 - 64 .
12. Ghosh N, C haki R, M andal V, M andal S C. C OX-2 as a target for cancer chemotherapy . Pharmacol Report 2010; 62 : 233 - 44 .
13. Rothwell P M, P rice J F, F owkes F G, Z anchetti A, Roncaglioni MC, Tognoni G, et al . Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: Analysis of the time course of risks and benefi ts in 51 randomised controlled trials . Lancet Epub 2012 Mar 24 .
14. Rothwell PM, W ilson M, P rice JF, B elch JF, M eade T W, Mehta Z . Effect of daily aspirin on risk of cancer metastasis: A study of incident cancers during randomised controlled trials . Lancet Epub 2012 Mar 24
15. Higgins JPT GSe . C ochrane handbook for systematic reviews of interventions Version 5 .1.0 updated March 2011]. The Cochrane Collaboration. Available from: http://www. cochrane-handbook.org.2011.
16. Gridelli C, G allo C, C eribelli A, G ebbia V, G amucci T, Ciardiello F, et al . Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: The GEmcitabine- COxib in NSCLC (GECO) study . Lancet Oncol 2007; 6 : 500 - 12 . (Pubitemid 46805905)
17. Dawson S J, M ichael M, B iagi J, F oo KF, J efford M, Ngan SY, et al . A phase I/II trial of celecoxib with chemotherapy and radiotherapy in the treatment of patients with locally advanced oesophageal cancer . Invest New Drugs 2007; 2 : 123 - 9 . (Pubitemid 46020870)
18. J ackson N A, B arrueco J, S oufi -Mahjoubi R, M arshall J, Mitchell E, Zhang X, et al . Comparing safety and effi cacy of fi rst-line irinotecan/fl uoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer: Findings from the bolus, infusional, or capecitabine with camptostar-celecoxib study . Cancer 2009 ; 12 : 2617 - 29 .
19. Preston T, F earon KC, M cMillan DC, W instanley FP, Slater C, Shenkin A, et al . Effect of ibuprofen on the acutephase response and protein metabolism in patients with cancer and weight loss . Br J Surg 1995; 2 : 229 - 34 .
20. Shinohara N, K umagai A, K anagawa K, M aruyama S, Abe T, Sazawa A, et al . Multicenter phase II trial of combination therapy with meloxicam, a COX-2 inhibitor, and natural interferon-alpha for metastatic renal cell carcinoma . Jap J Clin Oncol 2009; 11 : 720 - 6 .
21. Creagan ET, B uckner JC, H ahn RG, R ichardson RR, Schaid DJ, Kovach JS . An evaluation of recombinant leukocyte A interferon with aspirin in patients with metastatic renal cell cancer . Cancer 1988; 61 : 1787 - 91 .
22. Wigmore SJ, F alconer JS, P lester CE, R oss JA, M aingay JP, Carter DC, et al . Ibuprofen reduces energy expenditure and acute-phase protein production compared with placebo in pancreatic cancer patients . Br J Cancer 1995; 1 : 185 - 8 .
23. Hyltander A, K orner U, L undholm KG. E valuation of mechanisms behind elevated energy expenditure in cancer patients with solid tumours . Eur J Clin Invest 1993; 23 : 46 - 52 . (Pubitemid 23024969)
24. Mantovani G, M adeddu C, M accio A, G ramignano G, Lusso MR, Massa E, et al . Cancer-related anorexia/cachexia syndrome and oxidative stress: An innovative approach beyond current treatment . Cancer Epidemiol Biomarkers Prev 2004; 13 : 1651 - 9 . (Pubitemid 39331888)
25. Lindholm E, D aneryd P, Kör ner U, H yltander A, F ouladiun M, Lundholm K . Effects of recombinant erythropoietin in palliative treatment of unselected cancer patients . Clin Cancer Res 2004; 20 : 6855 - 64 . (Pubitemid 39383034)
26. Daneryd P. E poetin alfa for protection of metabolic and exercise capacity in cancer patients . Semin Oncol 2002; 29 (3 Suppl 8) : 69 - 74 . (Pubitemid 34686698)
27. Lundholm K, G elin J, H yltander A, L onnroth C, S andstrom R, Svaninger G, et al . Anti-inflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors . Cancer Res 1994; 54 : 5602 - 6 . (Pubitemid 24346254)
28. Lundholm K, D aneryd P, B osaeus I, Kör ner U, Lindholm E . Palliative nutritional intervention in addition to cyclooxygenase and erythropoietin treatment for patients with malignant disease: Effects on survival, metabolism, and function . Cancer 2004; 9 : 1967 - 77 . (Pubitemid 38529575)
29. Lundholm K, D aneryd P, K orner U, H yltander A, Bosaeus I . Evidence that long-term COX-treatment improves energy homeostasis and body composition in cancer patients with progressive cachexia . Int J Oncol 2004; 24 : 505 - 12 .
30. Lai V, G eorge J, R ichey L, K im H J, C annon T, S hores C, et al . Results of a pilot study of the effects of celecoxib on cancer cachexia in patients with cancer of the head, neck, and gastrointestinal tract . Head Neck 2008; 30 : 67 - 74.
31. M adeddu C, G ramignano G, M ulas C, F loris C, Sanna E, et al . A randomized phase III clinical trial of a combined treatment for cachexia in patients with gynecological cancers: Evaluating the impact on metabolic and inflammatory profi les and quality of life . Gynecol Oncol Epub 2011 Dec 27 .
32. Mantovani G, M accio A, M adeddu C, G ramignano G, Lusso MR, Serpe R, et al . A phase II study with antioxidants, both in the diet and supplemented, pharmaconutritional support, progestagen, and anti-cyclooxygenase-2 showing effi cacy and safety in patients with cancer-related anorexia/cachexia and oxidative stress . Cancer Epidemiol Biomarkers Prev 2006; 15 : 1030 - 4 . (Pubitemid 43823535)
33. Mantovani G, M acCio A, M adeddu C, S erpe R, A ntoni G, Massa E, et al . Phase II nonrandomized study of the effi cacy and safety of COX-2 inhibitor celecoxib on patients with cancer cachexia . J Mol Med 2010; 88 : 85 - 92 .
34. Cerchietti LC, N avigante A H, P eluffo GD, D iament MJ, Stillitani I, Klein SA, et al . Effects of celecoxib, medroxyprogesterone, and dietary intervention on systemic syndromes in patients with advanced lung adenocarcinoma: A pilot study . J Pain Symptom Manage 2004; 27 : 85 - 95 . (Pubitemid 38050252)
35. Cerchietti L C, N avigante AH, C astro M A. E ffects of eicosapentaenoic and docosahexaenoic n-3 fatty acids from fi sh oil and preferential Cox-2 inhibition on systemic syndromes in patients with advanced lung cancer . Nutr Cancer 2007; 59 : 14 - 20 . (Pubitemid 47549776)
36. McMillan D C, O 'Gorman P, F earon K C, M cArdle C S. A pilot study of megestrol acetate and ibuprofen in the treatment of cachexia in gastrointestinal cancer patients . Br J Cancer 1997; 76 : 788 - 90 . (Pubitemid 27379748)
37. McMillan DC, W igmore SJ, F earon KC, O 'Gorman P, Wright CE, McArdle CS. A prospective randomized study of megestrol acetate and ibuprofen in gastrointestinal cancer patients with weight loss . Br J Cancer 1999; 79 : 495 - 500 . (Pubitemid 29046225)
38. Osoba D, R odrigues G, M yles J, Z ee B, P ater J. I nterpreting the signifi cance of changes in health-related quality-of-life scores . J Clin Oncol 1998; 16 : 139 - 44 . (Pubitemid 28041591)
39. Jones L W, H ornsby W E, G oetzinger A, F orbes L M, Sherrard EL, Quist M, et al . Prognostic signifi cance of functional capacity and exercise behavior in patients with metastatic non-small cell lung cancer . Lung Cancer 2012; 76 : 248 - 52 .
40. McGettigan P, H enry D. C ardiovascular risk with nonsteroidal anti-inflammatory drugs: Systematic review of population-based controlled observational studies . PLoS Med 2011; 8 :e1001098.
41. Schlondorff D. R enal complications of nonsteroidal antiinflammatory drugs . Kidney Int 1993; 44 : 643 - 53 . (Pubitemid 23265236)
42. Cahlin C, K orner A, A xelsson H, W ang W, L undholm K, Svanberg E . Experimental cancer cachexia: The role of host-derived cytokines interleukin (IL)-6, IL-12, interferon-gamma, and tumor necrosis factor alpha evaluated in gene knockout, tumor-bearing mice on C57 Bl background and eicosanoid-dependent cachexia . Cancer Res 2000; 60 : 5488 - 93 .
43. Yao M, Z hou W, S angha S, A lbert A, C hang AJ, L iu T C, et al . Effects of nonselective cyclooxygenase inhibition with low-dose ibuprofen on tumor growth, angiogenesis, metastasis, and survival in a mouse model of colorectal cancer . Clin Cancer Res 2005; 11 : 1618 - 28 . (Pubitemid 40315247)
44. Ninomiya I, N agai N, O yama K, H ayashi H, T ajima H, Kitagawa H, et al . Antitumor and anti-metastatic effects of cyclooxygenase-2 inhibition by celecoxib on human colorectal carcinoma xenografts in nude mouse rectum . Oncol Report 2012; 28 : 777 - 84 .
45. Baris D, K aragas M R, K outros S, C olt J S, J ohnson A, Schwenn M, et al . Non-steroidal anti-inflammatory drugs (NSAIDs) and other analgesic use and bladder cancer in northern New England . Int J Cancer Epub 2012 Apr 17 .
46. Brasky TM, P otter JD, K ristal AR, P atterson RE, P eters U, Asgari MM, et al . Non-steroidal anti-inflammatory drugs and cancer incidence by sex in the VITamins And Lifestyle (VITAL) cohort . Cancer Cause Control 2012; 23 : 431 - 44 .
47. Groen HJ, S ietsma H, V incent A, H ochstenbag MM, van Putten JW, van den Berg A, et al . Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with advanced non-small-cell lung cancer: The NVALT-4 study . J Clin Oncol 2011; 29 : 4320 - 6 .
48. Davis T W, Z weifel BS, O 'Neal JM, H euvelman DM, A begg AL, Hendrich TO, et al . Inhibition of cyclooxygenase-2 by celecoxib reverses tumor-induced wasting . J Pharmacol Exp Therapeut 2004; 308 : 929 - 34 . (Pubitemid 38263967)
49. Peluffo GD, S tillitani I, R odriguez VA, D iament MJ, Klein SM . Reduction of tumor progression and paraneoplastic syndrome development in murine lung adenocarcinoma by nonsteroidal antiinflammatory drugs . Int J Cancer 2004; 110 : 825 - 30 . (Pubitemid 38758507)
50. Fearon KC, G lass DJ, G uttridge DC . C ancer cachexia: Mediators, signaling, and metabolic pathways . Cell Metab Epub 2012 Jul 17 .
51. Grosser T. V ariability in the response to cyclooxygenase inhibitors: Toward the individualization of nonsteroidal anti-inflammatory drug therapy . J Invest Med 2009; 57 : 709 - 16 .
52. Bertagnolli MM, E agle CJ, Z auber AG, Reds ton M, Breazna A, Kim K, et al . Five-year effi cacy and safety analysis of the Adenoma Prevention with Celecoxib Trial . Cancer Prev Res 2009; 2 : 310 - 21 .
53. Trelle S, R eichenbach S, W andel S, H ildebrand P, Tschannen B, Villiger PM, et al . Cardiovascular safety of non-steroidal anti-inflammatory drugs: Network metaanalysis . BMJ 2011; 342 :c7086.